Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course. This was analyzed at depth. Relax. I will lay it out. They are sister companies using Dr. Rutledge's/MIT Tech. Read the interview with Dr. Rutledge.
This is sister company (3D Matrix) that Dr. Rutledge created for regeneration.
Read this
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
Intellectual property came out of MIT for both
Based upon intellectual property:
3DM = Building and Regeneration
Arch= Stopping and Blocking
3DM is model T Ford whereas AC5 is the Tesla. I will post some of my research. Both operate in completely different areas. Arch perfected AC5 (recall what Dr. Rutledge said in his video that AC5 has been perfected from the original product-Arch hired the best people in world to perfect the product and has filed numerous patenta on).
3DM has been forced to go different route because of 2 failed human trials. I will document. 3DM no animal studies also. Whereas every rat and pig in the USA has been tested by Arch prior to human trials.
Intellectual property
3DM = Building and Regeneration
Arch= Stopping and Blocking
Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video
I have spent a lot of time studying 3 D Matrix. It is not a real competitor at all. No human trials. Yes CE Mark but no doctor will use with no human trials. They tried to do human trial in 2011 in Japan but failed--not because of safety at all. It passed on that count with flying colors.
This is sister company (3D Matrix) that Dr. Rutledge created for regeneration
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
Intellectual property came out of MIT for both
Based upon intellectual property:
3DM = Building and Regeneration
Arch= Stopping and Blocking
http://www.bloomberg.com/quote/7777:JP
Interesting thoughts. Thank you. Johnson and Johnson for example with say 60% of the market would be easier to get a "foothold" that you describe.
Agree with your external testing for agents added for tissue growth, etc. That is down the line.
If you search Europe for Pressure Ulcers for example you see it is a huge market. Who better qualified to role this out than a major company.
I am trying to understand what you are saying. There already was a multiple day human safety test.
IF the current human trial in Ireland is successful there will not be another human trial for exterior skin applications. It would not be necessary. Thus Pressure Ulcers and Foot ulcers are open. Maybe there will be some in future with additives to AC5.
IMHO this human trial is the equivalent of a phase 3 drug test.
Recall that they will seek CE Mark AND then a distribution JV in Europe after the results of these human trials. This is my understanding.
I hope we will see multiple human clinicals going on soon.
With only 4 employees and limited capital Arch is forced to go with major for distribution. The company has several ties into JNJ. It would be great if Arch survived several years but IMHO it just will not happen.
Of the 200 +/- POTENTIAL apps I bet a large percentage pertains to the exterior body. These IMO are the low hanging fruit for Arch and appear to me to be big $$.
As to burns....Thought: In the future AC5 will be combined with other agents to promote such things as healing, infection, etc. etc. etc. This will not be Arch but others who license AC5.
"Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection."
Where did you get that information.? From a Government website.
You are correct that the Arch website says $ 2 billion. IMHO they are being extremely conservative.... extremely
This is a Government website. It has to be right??/ Right?
http://www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html
Quote
"Did you know?
Number affected: 2.5 million patients per year.
Cost: Pressure ulcers cost $9.1-$11.6 billion per year in the US. Cost of individual patient care ranges from $20,900 to 151,700 per pressure ulcer. Medicare estimated in 2007 that each pressure ulcer added $43,180 in costs to a hospital stay.
Lawsuits: More than 17,000 lawsuits are related to pressure ulcers annually. It is the second most common claim after wrongful death and greater than falls or emotional distress.
Pain: Pressure ulcers may be associated with severe pain.
Death: About 60,000 patients die as a direct result of a pressure ulcer each year."
We are talking about TARGET markets for Arch's AC5 products which has some 200 +/- Potential applications such as Pressure Ulcers (bedsores) (2.5 million cases in USA each years costing $ 10 Billion), Foot Ulcers, Burns, etc, etc. This is the pipeline of potential products.
Here is one of the 200 Arch AC5 applications that has not been discussed: VENOUS ULCERS
What is a leg ulcer?
A leg ulcer is simply a break in the skin of the leg, which allows air and bacteria to get into the underlying tissue. This is usually caused by an injury, often a minor one that breaks the skin.
In most people such an injury will heal up without difficulty within a week or two. However, when there is an underlying problem the skin does not heal and the area of breakdown can increase in size. This is a chronic leg ulcer.
Here it is discussed in recent Arch Patent received:
http://www.archtherapeutics.com/news/press-releases/detail/471/arch-therapeutics-receives-notice-of-allowance-for-patent
"Many disorders are associated with leakage around blood vessels and within the tight junctions between cells. Such leakage can lead to fluid invading the tissues, causing a loss in blood pressure, organ dysfunction or failure, and death.
Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810192/
"In the United States it has been estimated that venous ulcers cause the loss of 2 million working days per year62. Venous ulcers account for 70%–90% of ulcers found on the lower leg63. The prevalence of venous ulcers in the U.S. is approximately 600,000 annually 64. In individuals 65 years and older, venous leg ulcers affect approximately 1.69% of the population in the U.S. 41. Venous leg ulcers cost approximately $9,600 to treat 41. The annual cost of treating venous ulcers to the US healthcare system is estimated at $2.5–3.5 billion.63"
Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810192/
http://www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html
This trial will not allow surgical use. That trial will be most likely be in 2017 in Europe. Thus the CE Mark will not apply to this use.
However the pressure ulcers, foot ulcers, burns will be good to go. We are talking huge markets.
Arch Therapeutics (ARTH)
A CLEAR LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE. How is that possible????
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund
The clear liquid medical device called AC5 is used to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care.
This is a most unusual medical device with vast impact on Surgery, Trauma Care, Wound Care (Pressure Ulcers, Foot Ulcers, Burns, etc), Military and other emergency situations. Human trials have begun in Ireland for this medical device.
OVER 200 Potential APPLICATIONS. Human trials have begun in Ireland for this medical device.
Elevator Summary of Arch http://www.archtherapeutics.blogspot.com/
The Cheapest Medical Device Stock I've Ever Seen By Michael Murphy CFA
http://seekingalpha.com/article/3286585-the-cheapest-medical-device-stock-ive-ever-seen
Arch Therapeutics (Symbol ARTH)
Website http://www.archtherapeutics.com/
Actually Pressure Ulcers, Foot Ulcers is the low hanging fruit of AC5. The $2 Billion is Britain alone. What about the rest of Europe?
For each Euro that Arch puts up in current human trials Ireland matches with two Euros. This program will last for seven years.
http://www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html
Did you know?
Number affected: 2.5 million patients per year.
Cost: Pressure ulcers cost $9.1-$11.6 billion per year in the US. Cost of individual patient care ranges from $20,900 to 151,700 per pressure ulcer. Medicare estimated in 2007 that each pressure ulcer added $43,180 in costs to a hospital stay.
Lawsuits: More than 17,000 lawsuits are related to pressure ulcers annually. It is the second most common claim after wrongful death and greater than falls or emotional distress.
Pain: Pressure ulcers may be associated with severe pain.
Death: About 60,000 patients die as a direct result of a pressure ulcer each year.
BK you have been doing your hoomwork !!
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
Arch's AC5 is the only CLEAR LIQUID noncoagulant homostatic agent that is classified as a MEDICAL DEVICE
Once again 200 +/- applications for AC5.
I see that you are posting the same posts on Yahoo also and receiving respones there also. Let me take a shot at a few.
Let's see. So they have enough cash to get through CE Mark in Europe. So they will joint venture with someone like JNJ who has 60% of the market now. JNJ does the distribution in Europe and Arch gets enough capital to do US testing.
Per Form 10-Q it will take $ 10- $ 14 million to get full Europe and US approvals. Small in biotech world. Outstanding warrants have raised many millions recently through exercise. More to come.
They have raised $ 12,990,669 since going public.
A lot of your questions are answered here:
http://www.archtherapeutics.blogspot.com/
A CLEAR LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE.
Arch Therapeutics (ARTH)
A CLEAR LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE. How is that possible?
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.
Due Diligence---Elevator Summary---
Elevator Summary of Arch Therapeutics: http://www.archtherapeutics.blogspot.com/
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
"The operation would be much shorter. We go from a bypass surgery that may take six hours to a bypass surgery that may take 45 minutes. Or a neurosurgery that may take three or four hours, to one that takes 20 minutes. So, it completely changes how you think about surgery.” “And it’s not just hemostasis. If you look at surgery for instance, let’s say we create a barrier that will stop the movement of bacteria. It will stop the growth of bacteria, and if you could stop the possible infection in that operating room, the recovery time would be faster.”
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection.
Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery (some have estimated potentially up to 60%).
"The operation would be much shorter. We go from a bypass surgery that may take six hours to a bypass surgery that may take 45 minutes. Or a neurosurgery that may take three or four hours, to one that takes 20 minutes. So, it completely changes how you think about surgery.” “And it’s not just hemostasis. If you look at surgery for instance, let’s say we create a barrier that will stop the movement of bacteria. It will stop the growth of bacteria, and if you could stop the possible infection in that operating room, the recovery time would be faster.”
http://www.pnas.org/site/misc/ellis-behnkePodcastTranscript.pdf
Presentation by Founder of AC5 Dr. Rutledge Ellis-Behnke PHD using AC5 on animals
AC5 Surgical HemostatTM is an Effective Hemostatic Agent in Anticoagulated Animals
You Tube Video
Well there are 200+/- potential applications for AC5. Pressure Ulcers /Bedsores alone afflicts 2.5 million people in US each year costing $ 10 billion(google this). Foot Ulcers-Burns- etc. etc etc. It is the only product that works with blood thinners.
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
Next Generation Medical Technology
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810192/
http://www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html
AC5 will be combined with all kinds of agents and it is not that far in the future.
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs.
Attributes of AC5
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
Next Generation Medical Technology
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems.
Friend mentioned that they may not be an additional financing now.
Warrants possibly being exercised.
3.4 million expiring 6/2/16 at $ .20
9.35 milion expring 2/14/19 with 44% already exercised at $.20
This would be about $ 2.5 million and last to 2/17. This is why price may be moving.
Anyone cnirm this with company???
Arch Therapeutics (ARTH)
Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
The Company has identified over 200 potential areas where AC5 could be used including: Surgery, Trauma Care, Wound Care, Military, Adhesions, Pressure Ulcers (Bedsores) (2.5 million cases in USA with annual cost $ 10 billion), Foot Ulcers, Burns, etc.
Human Clinical Trials have begun in Ireland. Total Europe and USA trial cost estimated to be $10 to $14 million.
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund
Arch Therapuetic AC5 Surgical Hemostatic Device
Synthetic peptide
Clear liquid, squirted or sprayed-- Can see and operate through it
Conforms to irregular wound geometry
Physical mechanical barrier (no metabolic activity or chemical activity with the body)
Classified as Medical Device in Europe because of no interaction with the body
No sign of interaction with human cell receptors or cell kinase enzymes
Stops bleeding promptly
Faster time to stop bleeding versus five different popular marketed products
Blood thinner agnostic—only hemostasis product that is.
Efficacy even in presence of “blood thinners”
Bioasborbable
Natural amino acids, non-animal
Enables normal healing
Non-cytotoxic, non-pyrogenic, non-irritant, non-sensitizer
Stores at room temperature
Indefinite shelf life
Simple, effective, versatile, safe universal
There are many other hemostatic agents, but:
* They all rely on using the patient's blood,
*They all take minutes to stop bleeding, not seconds
* None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch's AC5 product solves all these problems
Arch Therapeutics, Inc. ARTH
Faster, Safer, Simpler Surgery
The CEO is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund
A LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE !!!
Arch Therapuetics has Initiated Human Clinical Trials in Europe--200 potential applications including Pressure Ulcers (bedsores) 2.5 million cases USA with Annual Cost $10 Billion
o Arch is a small public company with a medical device pathway, relatively low capital requirements and potentially high margin novel products targeting large growing markets. Expect first product approval in 2016.
o Arch Medical Device: A LIQUID noncoagulant homostatic agent known as “AC5.” Works in presence of “blood thinners.”
Arch Therapeutics, Inc. is a medical device company developing totally disruptive technology to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Scientists at Massachusetts Institute of Technology invented this universal fix-all hemostat that works in a few seconds.
The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with potentially up to 60% savings in time of surgery. Spray AC5 on a bleeding artery and the bleeding stops without mechanical pressure being needed in seconds. This is disruptive industry technology.
AC5 stops bleeding promptly. AC5, is desperately needed by soldiers ("13 Hours"), surgery patients, those with foot ulcers or even bedsores (A $ 10 Billion US market). The Company has identified over 200 potential areas where AC5 could be used.
The Cheapest Medical Device Stock I've Ever Seen By Michael Murphy CFA
http://seekingalpha.com/article/3286585-the-cheapest-medical-device-stock-ive-ever-seen
Human Clinical trials have begun in Europe. Total Europe and USA trial cost $10 to $14 million---tiny for Biotech company !!
Watch CEO Dr. Terrence Norchi's presentation on 2/22/16 http://wsw.com/webcast/seethru15/arth
COMPANY Website http://www.archtherapeutics.com/
COMPANY Presentation ---Page 20 Pressure Ulcers (bedsores) -2.5 million cases USA Annual Cost $10 Billion
http://content.stockpr.com/archtherapeutics/media/a615ba3d0a9c00b0e77d846e84303000.pdf
Company Video
2020 product launch. So you would have thought for RCPI go after the easiest human trials to get on market quick. Anything. With 500,000 prior users they would have gotten prescribed product no matter what it was approved for. It does not take Einstein to figure it out. Very strange happening always with company. $ 4 price target really?
A friend sent me this. He said it was good. Anyone read what Murphy has to say about Arch? I don't own a kindle.
http://www.amazon.com/gp/product/B017MHU36Y?*Version*=1…
Bought a lot more. Thank you.
2020 ???? Pathetic. 5 more years. Go look at Prevagen the memory supplement.
You would have thought the Department of Defense would be funding millions of $ for further research
TBI Research Project Funding:
Listed below are TBI grants and contracts awarded to the Roskamp Institute (Years/Research Title/Grantor):
2013-2018
Chronic Effects of Neurotrauma Consortium. (Crawford)
Joint Veterans Affairs / Department of Defense
2010 – 2014
Identification and Validation of Novel Therapeutic Targets for Traumatic Brain Injury. (Crawford)
Department of Defense
2013 – 2015
Brain and Plasma Molecular Characterization of the Pathogenic TBI-AD Interrelationship in Mouse Models. (Crawford)
Department of Defense
2012 – 2015
Proteomic Identification of Plasma TBI Biomarkers. (Crawford)
Veterans Affairs
The TBI Research Program is also supported by the Roskamp Foundation.
How do you ascertain sells versus buys? Thanks
One wonders how others are able to obtain government funding for TBI research. This is an Australian company !!! Imagine what $25 million would do for RCPI. Note Fast track by FDA !!!
Investor presentation, 31 July 2015
http://bit.ly/1SPOakE>
Trofinetide in Traumatic Brain Injury (TBI)
? > 1.5 million head injuries annually in the US alone; >75% are mild (Concussion)
? Leading cause of death and disability, especially in young and elderly
? Serious health and economic effects of Concussion in sporting codes
Partnership funding of ~US$25 million by US Army[/b]
Phase 2 trial (“INTREPID”) in moderate to severe TBI
? Safety and efficacy of treatment with intravenous NNZ-2566 for 72 hours
? 260 subjects to be enrolled in US trauma centres – 245 enrolled to date
? “Fast Track” designation granted by the FDA
? Phase 2 trial in mild TBI (Concussion)
? Safety and efficacy of treatment with two dose levels of oral NNZ-2566 for 7 days
? 132 subjects with mild TBI to be enrolled at US military training facility
and civilian hospitals
? Trial timeline under review
That's Michael Murphy CFA who is forecasting $ 10 by year end.
The Cheapest Medical Device Stock I’ve Ever Seen
http://tinyurl.com/n9h5gf9
Did he talk about the $ 10 in the newsletter? What month did he come out with it in his newsletter?
Reason I am asking because it did not seem to have any effect if it was before July 1 and I believe it was.
Read Zen2Cents three comments to understand that the big boys are starting to take over the trading here. Not surprising at all.
The Cheapest Medical Device Stock I’ve Ever Seen
Comments here http://tinyurl.com/n9h5gf9
Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015
One of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements. It is projected that the industry may top $60 billion in 2021 according to the Nutritional Business Journal. Nutritional Supplement Companies, Retailers and Pharmaceutical Operations in focus today are Axxess Pharma Inc. (AXXE), Progressive Care Inc. (RXMD), USANA Health Sciences Inc. (USNA), GNC Holdings Inc. (GNC) and ARCA biopharma, Inc. (ABIO)
Axxess Pharma Inc. (AXXE) a company that develops a variety of nutritional supplements and specialty pharmaceutical products through its subsidiary company AllStar Health Brands Inc., is pleased to announce management projects a strong finish to the second half of 2015. Currently, 2015 has been a year of aggressive marketing and global approvals to sell their all-natural Tapout supplements. Axxess Pharma is also proud to be a licensee for Tapout, the official fitness and training partner of WWE (Worldwide Wrestling Entertainment) (NYSE: WWE). To view the joint venture between Authentic Brands Group, LLC and WWE for Tapout, please click on the link: http://corporate.wwe.com/news/2015/abg-and-wwe-launch-tapout-joint-venture.
I guess they are missing the best one.
Check your mailbox..... I will forward to you.
Trading stats are here http://ir.stockpr.com/archtherapeutics/historical-data
"Because ARTH will have only 100 million shares outstanding, these market capitalizations give target prices of $1 to $2 a share based on its current status, or $10 a share based on its status at the end of 2015."
The Cheapest Medical Device Stock I've Ever Seen
http://tinyurl.com/n9h5gf9 $ARTH
By Michael Murphy CFA
Perhaps people are finally taking notice of this company.
It is the Maxim Analyst report.
This comes from Investor Village board. Perhaps someone can put up above as description.
Arch Therapeutics Due Diligence
1) Review entire website http://www.archtherapeutics.com/
2) Review page by page latest presentation available :
http://ir.archtherapeutics.com/presentations
3) Read this article The Cheapest Medical Device Stock I’ve Ever Seen
http://tinyurl.com/n9h5gf9
By Michael Murphy CFA
“But sometimes the distance between price and value is startlingly wide. I have been analyzing stocks for over 45 years, and I can't remember ever seeing a distance this wide in a medical device stock”
4) Read and look at ALL the references in this summary of due diligence http://archtherapeutics.blogspot.com/
Watch the videos referenced. Read the analyst reports
CEO is MD, MIT MBA and former Portfolio Manager of one of the world’s largest healthcare mutual funds (Putnam) with $ 4 billion of assets.
“Still possibly one of the best medicine inventions of all time…a noncoagulant hemostatic agent.”
5) Video of CEO
That volume is equivalent to 57,954,325 pre split.... So bizarre.
Short interest is growing ..... Amazing
Short Int. AVG Daily volume
6/15/2015 755,668 492,834 1.533311
5/29/2015 663,781 65,404 10.148936
5/15/2015 651,548 50,765 12.834591
4/30/2015 591,418 74,560 7.932108
4/15/2015 575,378 54,120 10.631523
3/31/2015 557,728 32,039 17.407784
3/13/2015 559,712 23,906 23.413034
Thanks Buddahead. Check your messages.
I asked you a year ago what your CRP level is? You had a year supply? Just wonder what impact it has on your CRP levels.